floxacillin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, 6-aminopenicillanic acid derivatives	1183	5250-39-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: floxacillin fluocloxacilin flucloxacillin fluoxacillin flucloxacillin sodium	Antibiotic analog of CLOXACILLIN. Molecular weight: 453.87 Formula: C19H17ClFN3O5S CLOGP: 2.70 LIPINSKI: 0 HAC: 8 HDO: 2 TPSA: 112.74 ALOGS: -3.92 ROTB: 3

Molecule

Description

Molfile Inchi Smiles

Synonyms:

floxacillin
fluocloxacilin
flucloxacillin
fluoxacillin
flucloxacillin sodium

Antibiotic analog of CLOXACILLIN.

Molecular weight: 453.87
Formula: C19H17ClFN3O5S
CLOGP: 2.70
LIPINSKI: 0
HAC: 8
HDO: 2
TPSA: 112.74
ALOGS: -3.92
ROTB: 3

Drug dosage:

Dose	Unit	Route
2	g	O
2	g	P

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	146.96 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Hosey CM, Chan R, Benet LZ
BA (Bioavailability)	60 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.19 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.40 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.04 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.40 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.05 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1962	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Metabolic acidosis	336.18	25.69	136	6074	44933	63437879
Drug interaction	149.37	25.69	145	6065	228986	63253826
Cellulitis	114.80	25.69	81	6129	81877	63400935
Pyroglutamic acidosis	113.13	25.69	23	6187	612	63482200
Pyroglutamate increased	90.68	25.69	18	6192	423	63482389
Swelling face	56.52	25.69	48	6162	63427	63419385
Neutropenic sepsis	53.67	25.69	28	6182	16410	63466402
Jaundice	50.63	25.69	33	6177	29218	63453594
Hiccups	48.69	25.69	15	6195	2216	63480596
Dermatitis allergic	44.36	25.69	24	6186	15124	63467688
Vascular device infection	44.06	25.69	19	6191	7293	63475519
Rash erythematous	39.58	25.69	33	6177	42477	63440335
Perforation	39.23	25.69	11	6199	1172	63481640
Swollen tongue	38.75	25.69	30	6180	34770	63448042
Ejection fraction decreased	38.17	25.69	25	6185	22307	63460505
Eczema herpeticum	35.36	25.69	7	6203	162	63482650
Hypokalaemia	35.28	25.69	47	6163	103757	63379055
Lip swelling	35.07	25.69	27	6183	31036	63451776
Poor peripheral circulation	33.77	25.69	13	6197	3736	63479076
Acute kidney injury	32.18	25.69	76	6134	263339	63219473
Sepsis	31.65	25.69	55	6155	153068	63329744
Anterior interosseous syndrome	30.16	25.69	4	6206	4	63482808
Rash	29.13	25.69	120	6090	560751	62922061
Neuropathy peripheral	29.13	25.69	45	6165	113622	63369190
Vulvovaginal inflammation	28.73	25.69	8	6202	831	63481981
Polyhydramnios	28.30	25.69	10	6200	2261	63480551
Clostridium difficile infection	27.38	25.69	23	6187	29899	63452913
Angiodermatitis	27.25	25.69	5	6205	76	63482736
Acute haemorrhagic oedema of infancy	26.50	25.69	4	6206	16	63482796

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug interaction	153.02	21.58	167	4433	225779	34726552
Metabolic acidosis	147.71	21.58	84	4516	43596	34908735
Pyroglutamic acidosis	127.63	21.58	25	4575	401	34951930
Pyroglutamate increased	80.41	21.58	16	4584	279	34952052
Drug reaction with eosinophilia and systemic symptoms	69.47	21.58	47	4553	32965	34919366
Drug level decreased	62.23	21.58	27	4573	7819	34944512
Immunosuppressant drug level decreased	61.99	21.58	17	4583	1237	34951094
Stevens-Johnson syndrome	57.95	21.58	34	4566	18605	34933726
Kounis syndrome	38.76	21.58	14	4586	2504	34949827
Acute kidney injury	38.55	21.58	107	4493	304881	34647450
Genitalia external ambiguous	36.62	21.58	8	4592	223	34952108
Congenital bladder anomaly	35.00	21.58	8	4592	275	34952056
Foetal hypokinesia	32.57	21.58	8	4592	376	34951955
Neonatal respiratory depression	31.77	21.58	8	4592	417	34951914
Heart transplant rejection	31.40	21.58	10	4590	1221	34951110
Osteomyelitis salmonella	30.10	21.58	5	4595	29	34952302
Penile exfoliation	29.51	21.58	6	4594	117	34952214
Inhibitory drug interaction	28.30	21.58	10	4590	1678	34950653
Liver injury	26.17	21.58	19	4581	14859	34937472
Drug level below therapeutic	25.03	21.58	13	4587	5602	34946729
Blister	24.82	21.58	22	4578	22836	34929495
Cellulitis	23.82	21.58	32	4568	52919	34899412
Gastric ulcer	23.11	21.58	18	4582	15632	34936699
Lip swelling	22.68	21.58	18	4582	16062	34936269

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Metabolic acidosis	425.86	19.67	212	10538	82317	79651321
Drug interaction	283.14	19.67	312	10438	414871	79318767
Pyroglutamic acidosis	224.95	19.67	47	10703	1029	79732609
Pyroglutamate increased	166.35	19.67	34	10716	665	79732973
Cellulitis	104.84	19.67	99	10651	108961	79624677
Drug level decreased	104.81	19.67	47	10703	14355	79719283
Drug reaction with eosinophilia and systemic symptoms	61.07	19.67	58	10692	64186	79669452
Immunosuppressant drug level decreased	57.87	19.67	18	10732	1986	79731652
Acute kidney injury	56.77	19.67	176	10574	519228	79214410
Lip swelling	55.05	19.67	45	10705	40866	79692772
Swelling face	52.46	19.67	56	10694	71156	79662482
Stevens-Johnson syndrome	50.44	19.67	42	10708	39124	79694514
Jaundice	50.39	19.67	48	10702	53301	79680337
Dermatitis allergic	50.23	19.67	31	10719	18099	79715539
Drug level below therapeutic	49.93	19.67	25	10725	9745	79723893
Neutropenic sepsis	47.83	19.67	35	10715	27029	79706609
Swollen tongue	47.40	19.67	42	10708	42528	79691110
Clostridium difficile infection	47.30	19.67	42	10708	42643	79690995
Rash erythematous	40.04	19.67	44	10706	57725	79675913
Rash	39.32	19.67	168	10582	578190	79155448
Mouth swelling	38.52	19.67	18	10732	6033	79727605
Vascular device infection	34.80	19.67	20	10730	10256	79723382
Perforation	33.71	19.67	11	10739	1415	79732223
Kounis syndrome	31.23	19.67	14	10736	4268	79729370
Poor peripheral circulation	29.95	19.67	13	10737	3670	79729968
Penile exfoliation	29.72	19.67	6	10744	110	79733528
Heart transplant rejection	29.15	19.67	10	10740	1500	79732138
Eczema herpeticum	28.94	19.67	7	10743	301	79733337
Osteomyelitis salmonella	28.26	19.67	5	10745	43	79733595
Polyhydramnios	27.88	19.67	10	10740	1710	79731928
Chromaturia	27.86	19.67	25	10725	25721	79707917
Hypokalaemia	27.19	19.67	60	10690	143980	79589658
Angiodermatitis	25.77	19.67	5	10745	74	79733564
Lower respiratory tract infection	25.72	19.67	55	10695	129165	79604473
Liver function test abnormal	25.33	19.67	37	10713	64438	79669200
Blister	25.11	19.67	52	10698	119424	79614214
Ejection fraction decreased	25.11	19.67	27	10723	34550	79699088
Acidosis	25.04	19.67	21	10729	19741	79713897
Angioedema	24.76	19.67	40	10710	75995	79657643
Congenital bowing of long bones	24.48	19.67	4	10746	20	79733618
Vaginal discharge	23.88	19.67	14	10736	7449	79726189
Anterior interosseous syndrome	23.87	19.67	4	10746	24	79733614
Strawberry tongue	23.87	19.67	4	10746	24	79733614
Skin exfoliation	23.67	19.67	33	10717	55067	79678571
Anaphylactic reaction	23.21	19.67	41	10709	83702	79649936
Completed suicide	22.97	19.67	3	10747	245764	79487874
Malaise	22.93	19.67	128	10622	489741	79243897
Pustule	22.74	19.67	9	10741	2016	79731622
Hiccups	22.46	19.67	15	10735	10016	79723622
Repetitive strain injury	22.35	19.67	5	10745	152	79733486
Gastric ulcer	22.07	19.67	25	10725	33880	79699758
Toxic epidermal necrolysis	21.12	19.67	28	10722	44553	79689085
Pharyngeal swelling	20.88	19.67	13	10737	7706	79725932
Acute haemorrhagic oedema of infancy	20.63	19.67	4	10746	59	79733579
Vulvovaginal inflammation	20.48	19.67	6	10744	540	79733098
Death	20.38	19.67	28	10722	566486	79167152

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01CF05	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE BETA-LACTAM ANTIBACTERIALS, PENICILLINS Beta-lactamase resistant penicillins
CHEBI has role	CHEBI:36047	antibacterial drugs
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.76	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Type	Activity value (-log[M])	Bioact source
Androgen receptor	Nuclear hormone receptor	P10275	ANDR_HUMAN	IC50	6.25	WOMBAT-PK
Matrix metalloproteinase-9	Enzyme	P14780	MMP9_HUMAN	IC50	4.19	WOMBAT-PK
Penicillin-binding protein 1A	Enzyme		PBPA_CLOPE			WOMBAT-PK

External reference:

ID	Source
N0000167002	NUI
D01249	KEGG_DRUG
C0016267	UMLSCUI
CHEBI:5098	CHEBI
CHEMBL222645	ChEMBL_ID
D005436	MESH_DESCRIPTOR_UI
DB00301	DRUGBANK_ID
10910	IUPHAR_LIGAND_ID
21319	PUBCHEM_CID
235750	RXNORM
003516	NDDF
003517	NDDF
387544009	SNOMEDCT_US
426208000	SNOMEDCT_US
96067005	SNOMEDCT_US
2308	INN_ID
43B2M34G2V	UNII

Pharmaceutical products:

None